JP2019519544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519544A5 JP2019519544A5 JP2018564829A JP2018564829A JP2019519544A5 JP 2019519544 A5 JP2019519544 A5 JP 2019519544A5 JP 2018564829 A JP2018564829 A JP 2018564829A JP 2018564829 A JP2018564829 A JP 2018564829A JP 2019519544 A5 JP2019519544 A5 JP 2019519544A5
- Authority
- JP
- Japan
- Prior art keywords
- vedolizumab
- dose
- composition
- responder
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349026P | 2016-06-12 | 2016-06-12 | |
| US62/349,026 | 2016-06-12 | ||
| PCT/US2017/037072 WO2017218434A1 (en) | 2016-06-12 | 2017-06-12 | Method of treating inflammatory bowel disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519544A JP2019519544A (ja) | 2019-07-11 |
| JP2019519544A5 true JP2019519544A5 (enExample) | 2020-07-27 |
| JP7202893B2 JP7202893B2 (ja) | 2023-01-12 |
Family
ID=59270123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564829A Active JP7202893B2 (ja) | 2016-06-12 | 2017-06-12 | 炎症性腸疾患を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11389533B2 (enExample) |
| EP (1) | EP3468597A1 (enExample) |
| JP (1) | JP7202893B2 (enExample) |
| CN (1) | CN109414502A (enExample) |
| CA (1) | CA3027286A1 (enExample) |
| MA (1) | MA45245A (enExample) |
| WO (1) | WO2017218434A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US20240254243A1 (en) * | 2021-06-17 | 2024-08-01 | Prometheus Laboratories Inc. | Systems and methods for improved targeted therapy |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| EP0808367B1 (en) | 1995-02-10 | 2007-07-11 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins and uses thereof |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| JPWO2002078779A1 (ja) | 2001-03-27 | 2004-07-22 | 日本ゼオン株式会社 | 医療用ガイドワイヤ |
| EP1784426B1 (en) | 2004-09-03 | 2011-11-23 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| US20070122404A1 (en) | 2005-11-17 | 2007-05-31 | O'keefe Theresa L | Humanized immunoglobulin reactive with alpha4beta7 integrin |
| WO2010107752A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| LT2704742T (lt) * | 2011-05-02 | 2017-10-25 | Millennium Pharmaceuticals, Inc. | Anti-alfa4beta7 antikūno kompozicija |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2016086147A1 (en) * | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| MX392140B (es) | 2015-06-08 | 2025-03-21 | Univ Washington | Composiciones y uso de las mismas para tratar la enfermedad celiaca. |
| KR102710759B1 (ko) | 2016-03-14 | 2024-09-25 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 이식편대숙주 질환을 예방하는 방법 |
| CA3017758A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| WO2017165778A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| MA44864A (fr) | 2016-05-04 | 2019-03-13 | Icahn School Med Mount Sinai | Trithérapie pour le traitement d'une maladie intestinale inflammatoire |
-
2017
- 2017-06-12 WO PCT/US2017/037072 patent/WO2017218434A1/en not_active Ceased
- 2017-06-12 CN CN201780041382.4A patent/CN109414502A/zh active Pending
- 2017-06-12 JP JP2018564829A patent/JP7202893B2/ja active Active
- 2017-06-12 MA MA045245A patent/MA45245A/fr unknown
- 2017-06-12 CA CA3027286A patent/CA3027286A1/en active Pending
- 2017-06-12 US US16/309,002 patent/US11389533B2/en active Active
- 2017-06-12 EP EP17734895.0A patent/EP3468597A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Korean Association for the Study of the Liver (KASL | KASL clinical practice guidelines: management of chronic hepatitis B | |
| D'Elia et al. | Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. | |
| Zang et al. | IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection | |
| JP2022033891A (ja) | 関節リウマチを治療するための組成物およびこれを使用する方法 | |
| US9980960B2 (en) | Methods for determining the risk of cardiovascular disease in a subject having a chronic viral infection | |
| JP2019519544A5 (enExample) | ||
| JP7101479B2 (ja) | 関節リウマチ患者の健康に関連した生活の質を改善するための組成物 | |
| JP2018515493A5 (enExample) | ||
| JP2019505553A (ja) | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 | |
| Ruocco et al. | Life-threatening bullous dermatoses: Pemphigus vulgaris | |
| JP2020502261A5 (enExample) | ||
| Uojima et al. | Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: a randomized study | |
| Freedman et al. | Twenty years of subcutaneous interferon-Beta-1a for multiple sclerosis: contemporary perspectives | |
| Melica et al. | Primary vasculitis of the central nervous system in patients infected with HIV‐1 in the HAART era | |
| JP7495403B2 (ja) | 巨細胞性動脈炎の治療 | |
| Ernestam et al. | Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. | |
| Bascones-Martinez et al. | Oral manifestations of pemphigus vulgaris: clinical presentation, differential diagnosis and management | |
| TWI569808B (zh) | 肝細胞腫瘤（ｈｃｃ）之治療 | |
| Kameda et al. | Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab | |
| Stavinoha et al. | Current therapy of chronic liver disease | |
| Das et al. | Unusual and lesser-known rare causes of adult growth hormone deficiency | |
| JP2019505598A5 (enExample) | ||
| Hirosawa et al. | No regional disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 infection in Tochigi prefecture and its vicinity | |
| US20250161336A1 (en) | Treatment of adenovirus infection or disease associated with adenovirus infection | |
| Rizvi | Disease-Modifying Agents |